Cargando…

Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions

BACKGROUND. Although it is widely accepted that adults with immunocompromising conditions are at greatly increased risk of pneumococcal infection, the extent of risk among immunocompetent adults with chronic medical conditions is less certain, particularly in the current era of universal vaccinatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shea, Kimberly M., Edelsberg, John, Weycker, Derek, Farkouh, Raymond A., Strutton, David R., Pelton, Stephen I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324183/ https://www.ncbi.nlm.nih.gov/pubmed/25734097 http://dx.doi.org/10.1093/ofid/ofu024

Ejemplares similares

Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions
por: Weycker, Derek, et al.
Publicado: (2016)

Rethinking Risk for Pneumococcal Disease in Adults: The Role of Risk Stacking
por: Pelton, Stephen I., et al.
Publicado: (2015)

Rates of pneumonia among children and adults with chronic medical conditions in Germany
por: Pelton, Stephen I., et al.
Publicado: (2015)

Excess Risk of Invasive Pneumococcal Disease (IPD) Persists in Adults with Comorbid Conditions in the Era of PCV13 Childhood and Adult Immunization
por: Pelton, Stephen I, et al.
Publicado: (2017)

Decline in Pneumococcal Disease Attenuated in Older Adults and Those With Comorbidities Following Universal Childhood PCV13 Immunization
por: Pelton, Stephen I, et al.
Publicado: (2019)

Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease
por: Bornheimer, Rebecca, et al.
Publicado: (2017)

Pneumonia in young adults with asthma: impact on subsequent asthma exacerbations
por: Pelton, Stephen I, et al.
Publicado: (2019)

1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
por: Yildirim, Inci, et al.
Publicado: (2018)

2207. Rates of Lower Respiratory Tract Infections Among US Adults Aged ≥18 Years With and Without Chronic Medical Conditions
por: Weycker, Derek, et al.
Publicado: (2022)

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
por: Strutton, David R, et al.
Publicado: (2012)

Improving Influenza and Pneumococcal Vaccination Rates in Ambulatory Specialty Practices
por: Pennant, Keyana N., et al.
Publicado: (2015)

1095 Invasive Pneumococcal Disease in Children with Underlying Conditions Has Higher Case Fatality and Unique Serotype Distribution
por: Yildirim, Inci, et al.
Publicado: (2014)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Pneumococcal Conjugate Vaccine Safety in Elderly Adults
por: Tseng, Hung Fu, et al.
Publicado: (2018)

1404. Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age
por: Lapidot, Rotem, et al.
Publicado: (2020)

Homelessness in Adults With Invasive Pneumococcal Disease in Calgary, Canada
por: Lemay, Julie-Anne, et al.
Publicado: (2019)

Risk of Pneumococcal Disease in US Adults by Age and Risk Profile
por: Grant, Lindsay R, et al.
Publicado: (2023)

Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children
por: Lapidot, Rotem, et al.
Publicado: (2017)

Factors Associated With Severe Nonmeningitis Invasive Pneumococcal Disease in Adults in France
por: Danis, Kostas, et al.
Publicado: (2019)

Pneumococcal and influenza vaccination rates and their determinants in children with chronic medical conditions
por: Giannattasio, Antonietta, et al.
Publicado: (2010)

1514. Mortality and Readmission in Adults during the First Year Following Hospitalization for Community-Acquired Pneumonia in the US
por: Sato, Reiko, et al.
Publicado: (2020)

Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
por: Lapidot, Rotem, et al.
Publicado: (2020)

1510. Infant Pneumonia and Subsequent Risk of Chronic Respiratory Disorders
por: Pelton, Stephen I, et al.
Publicado: (2020)

Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules
por: Edelsberg, John, et al.
Publicado: (2018)

A Leukocyte Score to Improve Clinical Outcome Predictions in Bacteremic Pneumococcal Pneumonia in Adults
por: Blot, Mathieu, et al.
Publicado: (2014)

Decreased Pneumococcal Carriage Among Older Adults in Denmark During the COVID-19 Lockdown
por: Tinggaard, Michaela, et al.
Publicado: (2023)

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
por: Wasserman, Matt, et al.
Publicado: (2021)

Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
por: Weycker, Derek, et al.
Publicado: (2013)

Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis
por: Weycker, Derek, et al.
Publicado: (2014)

Antiretroviral Therapy as Prevention of … Pneumococcal Infections?
por: Lesourd, Anaïs, et al.
Publicado: (2016)

1105 Chronic Kidney Disease and Invasive Pneumococcal Disease in Adults
por: Baxter, Roger, et al.
Publicado: (2014)

Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination
por: Grant, Lindsay R, et al.
Publicado: (2022)

Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis
por: McLaughlin, John M, et al.
Publicado: (2022)

Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY)
por: Hammitt, Laura L, et al.
Publicado: (2021)

2555. Predicting Risk of Breakthrough Invasive Pneumococcal Disease in Children After 13-Valent Pneumococcal Conjugate Vaccination
por: Yildirim, Melike, et al.
Publicado: (2018)

White Blood Cell Counts, Alcoholism, and Cirrhosis in Pneumococcal Pneumonia
por: Gardner, Julianna G., et al.
Publicado: (2017)

Pneumococcal Carriage, Serotype Distribution, and Risk Factors in Children With Community-Acquired Pneumonia, 5 Years After Introduction of the 10-Valent Pneumococcal Conjugate Vaccine in Ethiopia
por: Negash, Abel Abera, et al.
Publicado: (2019)

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
por: Atwood, Mark, et al.
Publicado: (2018)

Nasopharyngeal Pneumococcal Density Is Associated With Viral Activity but Not With Use of Improved Stoves Among Young Andean Children
por: Howard, Leigh M, et al.
Publicado: (2017)

2704. Molecular Technology to Detect Pneumococcal Colonization in Young Children Reveals Increased Prevalence of Vaccine Serotypes as Compared with Enhanced Culture Methods
por: Pelton, Stephen I, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ims1h0ioh7b52v0ajffgrgud3t